Sun Pharmaceutical Industries Shares Rise by 2.13% in Today's Trading

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

During today's trading session, Sun Pharmaceutical Industries experienced a notable increase, with its shares rising by 2.13 percent to Rs 1726.60. This price movement has drawn the attention of investors, marking a significant event for the pharmaceutical giant.

Sun Pharma stock is a constituent of both the NIFTY 50 and NIFTY 100 indices, reflecting its importance in the Indian stock market.

Financial Performance

Sun Pharmaceutical Industries has demonstrated consistent financial performance over the past few years. A review of the company's consolidated financials provides insights into its revenue, net profit, and earnings per share (EPS).

• March 2025: Revenue was Rs 12,958.84 Crores, with a net profit of Rs 2,160.64 Crores and EPS of Rs 9.00.
• December 2024: Revenue was Rs 13,675.46 Crores, with a net profit of Rs 2,917.54 Crores.
• September 2024: Revenue was Rs 13,291.39 Crores, with a net profit of Rs 3,030.67 Crores.

• March 2025: Revenue reached Rs 52,578.44 Crores, accompanied by a net profit of Rs 10,980.10 Crores and EPS of Rs 45.60.
• March 2024: Revenue stood at Rs 48,496.85 Crores, with a net profit of Rs 9,648.44 Crores and EPS of Rs 39.90.
• March 2023: Revenue was Rs 43,885.68 Crores, with a net profit of Rs 8,560.84 Crores and EPS of Rs 35.30.

• Book Value per Share: Rs 301.00
• Return on Equity: 15.13%
• Debt to Equity: 0.03

The company's financial data indicates a robust growth trajectory with consistent increases in revenue and net profit over the years. The strong return on equity and low debt-to-equity ratio further highlight the company's financial stability and efficiency.

Additional Financial Insights

The income statement analysis reveals consistent performance. For the year ended March 2025, Sun Pharmaceutical Industries reported total income of Rs 54,543 Crores and total expenditure of Rs 40,559 Crores, resulting in an EBIT of Rs 13,983 Crores. The company's interest expenses were Rs 231 Crores, and tax expenses were Rs 2,772 Crores.

From a cash flow perspective, the company generated Rs 14,072 Crores from operating activities and had a net cash flow of Rs 983 Crores for the year ended March 2025. The balance sheet shows total assets of Rs 92,100 Crores, with Rs 20,290 Crores in fixed assets and Rs 52,624 Crores in current assets.

The per share ratios indicate a basic EPS of Rs 45.60 and a diluted EPS of Rs 45.60 for March 2025. The company's dividend per share was Rs 16.00. Valuation ratios show a P/E ratio of 38.04 and a P/B ratio of 5.77 for March 2025.

The financial strength and market positioning of Sun Pharmaceutical Industries reflect its significance within the Indian pharmaceutical sector.

Moneycontrol analysis indicates a bearish sentiment as of June 9, 2025.

With Sun Pharmaceutical Industries' current price at Rs 1726.60, the stock reflects a positive trend in today's trading session.